Table 3.
A review on COVID-19 peptide immune modulators: Clinical studies
| Peptide design | Phase | References |
|---|---|---|
| Thymic peptides | II | Zaldívar (2021) |
| Interferon Beta-1A | IV | Beta and 1a in hospitalized COVID-19 patients (2021) |
| Infliximab, Abatacept | III | Immune modulators for treating COVID-19 (2021) |
| Thymalfasin | II | Rhode Island Hospital (2021) |
| Combination product: AZD7442 (antibody combination: non-vaccine) | I | AstraZeneca (2021) |
| Pegylated interferon α2b | II | Cadila Healthcare Limited (2021) |
| Interleukin-7 | II | Revimmune (2021) |
| Tocilizumab | II | University Hospital Inselspital (2020) |
| Hyper immunoglobulins containing anti-corona VS2 immunoglobulin | – | Mohamed (2020) |
| LSALT peptide | II | Arch Biopartners Inc (2021) |
| Glycine | – | Vargas (2020) |